Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 6/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 3/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14754800 | 0.84 | ALDH1A1 (0.47) | PDE1BNPBWR1ALDH1A1LMNAMAPT | |
| SCHEMBL30844170 | 0.80 | NPBWR1 (0.45) | PDE1BNPBWR1ALDH1A1LMNAMAPT | |
| SCHEMBL4789449 | 0.80 | PDE1B (0.46) | PDE1BNPBWR1ALDH1A1LMNAMAPT | |
| SCHEMBL530059 | 0.80 | IDO1 (0.47) | PDE1BNPBWR1MAPTMCHR1PDE1A | |
| SCHEMBL21796474 | 0.80 | NPBWR1 (0.44) | PDE1BNPBWR1ALDH1A1LMNAMAPT | |
| SCHEMBL23210996 | 0.79 | GRIN1 (0.58) | PDE1BNPBWR1 | |
| SCHEMBL29071647 | 0.78 | NPBWR1 (0.48) | PDE1BNPBWR1ALDH1A1LMNAMAPT | |
| SCHEMBL17395029 | 0.78 | NPBWR1 (0.48) | PDE1BNPBWR1ALDH1A1LMNAMAPT | |
| SCHEMBL30487302 | 0.78 | NPBWR1 (0.48) | PDE1BNPBWR1ALDH1A1LMNAMAPT | |
| SCHEMBL21796592 | 0.78 | CNR2 (0.41) | PDE1BNPBWR1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535401-A | Novel PARP1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| CN-113372342-B | Protein degradation targeting chimera and application thereof | 暨南大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-113372342-A | Protein degradation targeting chimera and application thereof | 暨南大学 | 2021-09-10 | — | — | CN | disclosed |
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2015-03-05 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | PDE1B 2550/4885NPBWR1 4716/4885ALDH1A1 615/4885 |
| US-20150065468-A1 | BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF | ERBB2, ERBB3, AADAC | PDE1B 1222/4885NPBWR1 946/4885ALDH1A1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.